Shu Niu

Shijiazhuang, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Oral microbiome signatures of post-stroke cognitive impairment.

Oral microbiome signatures of post-stroke cognitive impairment.

Journal: Frontiers in microbiology
Published: October 13, 2025

Combined Transcriptome and Metabolome Analyses of Oxidative Stress Regulatory Mechanism in Porcine Follicular Granulosa Cells.

Combined Transcriptome and Metabolome Analyses of Oxidative Stress Regulatory Mechanism in Porcine Follicular Granulosa Cells.

Journal: Biology
Published: September 15, 2025

Corrigendum to "A metabonomics-based renoprotective mechanism analysis of empagliflozin in obese mice" [Biochem. Biophys. Res. Commun. 621 (2022) 122-129].

Corrigendum to "A metabonomics-based renoprotective mechanism analysis of empagliflozin in obese mice" [Biochem. Biophys. Res. Commun. 621 (2022) 122-129].

Journal: Biochemical and biophysical research communications
Published: September 04, 2025

Risk factor analysis of cognitive frailty in older adults with type 2 diabetes mellitus: a cross-sectional study.

Risk factor analysis of cognitive frailty in older adults with type 2 diabetes mellitus: a cross-sectional study.

Journal: Frontiers in aging neuroscience
Published: July 16, 2025

Multi-omics analysis of hepatic outcomes in T2DM-MAFLD patients treated with semaglutide: a single-centre, longitudinal, data-driven study.

Multi-omics analysis of hepatic outcomes in T2DM-MAFLD patients treated with semaglutide: a single-centre, longitudinal, data-driven study.

Journal: Frontiers in endocrinology
Published: June 20, 2025

Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice.

Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice.

Journal: World journal of hepatology
Published: June 05, 2025

Corrigendum to "Empagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism".

Corrigendum to "Empagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism".

Journal: Open medicine (Warsaw, Poland)
Published: January 06, 2025

Empagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism.

Empagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism.

Journal: Open medicine (Warsaw, Poland)
Published: February 18, 2024

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice.

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: June 09, 2023

Mechanisms of Small Intestine Involvement in Obesity-Induced Atherosclerosis.

Mechanisms of Small Intestine Involvement in Obesity-Induced Atherosclerosis.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: May 17, 2023

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model.

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model.

Journal: Frontiers in endocrinology
Published: September 16, 2022

Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice.

Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice.

Journal: Drug design, development and therapy
Published: July 23, 2022
Showing 1-12 of 22

Last Updated: 09/26/2026